drugset
drugset / Trial / NCT05296382

Bioavailability of Tebipenem (SPR994) Crushed Tablet

NCT05296382 ↗

Phase 1 Completed 12 enrolled Hartford Hospital Spero Therapeutics · collab
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to measure the amount of the antibiotic, tebipenem (SPR994) that is bioavailable after crushing the tablet and administering through a feeding tube with and without tube feeds.

Timeline

Start
2022-04-01
Primary completion
2022-06-01
Completion
2022-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Tebipenem Small molecule 600 mg Oral

Indications

No indication recorded.